Lifeloc reports FY2024 net loss of $1.05M on revenue down 8% to $8.54M

Lifeloc Technologies, Inc

2025-Q1 EPS reported -$0.11 revenue$2,277,034

Net loss of $1.053M ($0.41 diluted EPS) vs net profit of $205.6K ($0.08 EPS) in 2023.
Revenue declined 8% to $8.538M from $9.330M; gross margin fell to 40.4% from 43.3%.
Record R&D investment in SpinDx drug detection; beta testing of THC disk in Q2 2025, commercial launch early 2026.
Closed $750K debenture in Dec 2024 plus $75K in Q1 2025 to fund SpinDx development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.